PMID- 32469686
OWN - NLM
STAT- MEDLINE
DCOM- 20210614
LR  - 20211022
IS  - 2688-1535 (Electronic)
IS  - 2688-1527 (Print)
IS  - 2688-1527 (Linking)
VI  - 16
IP  - 10
DP  - 2020 Oct
TI  - Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis 
      From Across the United States.
PG  - e1169-e1180
LID - 10.1200/JOP.19.00639 [doi]
AB  - PURPOSE: Multiple myeloma (MM) treatment has changed tremendously, with 
      significant improvement in patient out-comes. One group with a suboptimal benefit 
      is patients with high-risk cytogenetics, as tested by conventional karyotyping or 
      fluorescence in situ hybridization (FISH). Methodology for these tests has been 
      published, but not necessarily standardized. METHODS: We address variability in 
      the testing and reporting methodology for MM cytogenetics in the United States 
      using the ongoing African American Multiple Myeloma Study (AAMMS). We evaluated 
      clinical and cytogenetic data from 1,221 patients (1,161 with conventional 
      karyotyping and 976 with FISH) tested between 1998 and 2016 across 58 
      laboratories nationwide. RESULTS: Interlab and intralab variability was noted for 
      the number of cells analyzed for karyotyping, with a significantly higher number 
      of cells analyzed in patients in whom cytogenetics were normal (P 5.0025). For 
      FISH testing, CD138-positive cell enrichment was used in 29.7% of patients and no 
      enrichment in 50% of patients, whereas the remainder had unknown status. A 
      significantly smaller number of cells was analyzed for patients in which CD138 
      cell enrichment was used compared with those without such enrichment (median, 50 
      v 200; P, .0001). A median of 7 loci probes (range, 1-16) were used for FISH 
      testing across all laboratories, with variability in the loci probed even within 
      a given laboratory. Chromosome 13-related abnormalities were the most frequently 
      tested abnormality (n5956; 97.9%), and t(14;16) was the least frequently tested 
      abnormality (n 5 119; 12.2%). CONCLUSIONS: We report significant variability in 
      cytogenetic testing across the United States for MM, potentially leading to 
      variability in risk stratification, with possible clinical implications and 
      personalized treatment approaches.
FAU - Yu, Yang
AU  - Yu Y
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Brown Wade, Niquelle
AU  - Brown Wade N
AUID- ORCID: 0000-0001-7405-8772
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Hwang, Amie E
AU  - Hwang AE
AUID- ORCID: 0000-0002-5538-131X
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Nooka, Ajay K
AU  - Nooka AK
AUID- ORCID: 0000-0003-4165-6869
AD  - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, GA.
FAU - Fiala, Mark A
AU  - Fiala MA
AUID- ORCID: 0000-0002-0208-5023
AD  - Division of Oncology, Washington University School of Medicine, Saint Louis, MO.
FAU - Mohrbacher, Ann
AU  - Mohrbacher A
AD  - Department of Medicine, Division of Hematology, University of Southern 
      California, Los Angeles, CA.
FAU - Peters, Edward S
AU  - Peters ES
AD  - Louisiana State University School of Public Health, New Orleans, LA.
FAU - Pawlish, Karen
AU  - Pawlish K
AD  - New Jersey Department of Health, Trenton, NJ.
FAU - Bock, Cathryn
AU  - Bock C
AD  - Karmanos Cancer Center, Wayne State University, Detroit, MI.
FAU - Van Den Berg, David J
AU  - Van Den Berg DJ
AUID- ORCID: 0000-0002-5404-5218
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Rand, Kristin A
AU  - Rand KA
AD  - Ancestry.com, San Francisco, CA.
FAU - Stram, Daniel
AU  - Stram D
AD  - Ancestry.com, San Francisco, CA.
FAU - Conti, David V
AU  - Conti DV
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Auclair, Daniel
AU  - Auclair D
AUID- ORCID: 0000-0001-5151-3058
AD  - Multiple Myeloma Research Foundation, Norwalk, CT.
FAU - Colditz, Graham A
AU  - Colditz GA
AD  - Division of Oncology, Washington University School of Medicine, Saint Louis, MO.
FAU - Mehta, Jayesh
AU  - Mehta J
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
FAU - Haiman, Christopher A
AU  - Haiman CA
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
FAU - Terebelo, Howard
AU  - Terebelo H
AD  - Providence Hospital, Southfield, MI.
FAU - Janakiraman, Nalini
AU  - Janakiraman N
AD  - Division of Hematology-Oncology, Henry Ford Hospital, Detroit, MI.
FAU - Singhal, Seema
AU  - Singhal S
AD  - Feinberg School of Medicine, Northwestern University, Chicago, IL.
FAU - Chiu, Brian
AU  - Chiu B
AD  - Department of Public Health Sciences, University of Chicago, Chicago, IL.
FAU - Vij, Ravi
AU  - Vij R
AUID- ORCID: 0000-0001-8795-3610
AD  - Division of Oncology, Washington University School of Medicine, Saint Louis, MO.
FAU - Bernal-Mizrachi, Leon
AU  - Bernal-Mizrachi L
AD  - Grady Memorial Hospital, Emory University, Atlanta, GA.
FAU - Zonder, Jeffrey A
AU  - Zonder JA
AUID- ORCID: 0000-0002-1741-2795
AD  - Karmanos Cancer Center, Wayne State University, Detroit, MI.
FAU - Huff, Carol A
AU  - Huff CA
AUID- ORCID: 0000-0003-0545-0708
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, 
      MD.
FAU - Lonial, Sagar
AU  - Lonial S
AD  - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, GA.
FAU - Orlowski, Robert Z
AU  - Orlowski RZ
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, TX.
FAU - Cozen, Wendy
AU  - Cozen W
AUID- ORCID: 0000-0003-3415-8247
AD  - Department of Preventive Medicine, Center for Genetic Epidemiology, Keck School 
      of Medicine of USC, University of Southern California, Los Angeles, CA.
AD  - Department of Pathology, Keck School of Medicine of USC, University of Southern 
      California, Los Angeles, CA.
FAU - Ailawadhi, Sikander
AU  - Ailawadhi S
AUID- ORCID: 0000-0002-8377-8111
AD  - Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL.
LA  - eng
GR  - P50 CA186781/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200529
PL  - United States
TA  - JCO Oncol Pract
JT  - JCO oncology practice
JID - 101758685
SB  - IM
CIN - 10.1200/JOP.19.00309
MH  - Cytogenetic Analysis/*standards
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - *Multiple Myeloma/diagnosis/genetics
MH  - United States
PMC - PMC7564132
COIS- VARIABILITY IN CYTOGENETIC TESTING FOR MULTIPLE MYELOMA: A COMPREHENSIVE ANALYSIS 
      FROM ACROSS THE UNITED STATES: The following represents disclosure information 
      provided by authors of this manuscript. All relationships are considered 
      compensated unless otherwise noted. Relationships are self-held unless noted. I = 
      Immediate Family Member, Inst = My Institution. Relationships may not relate to 
      the subject matter of this manuscript. For more information about ASCO's conflict 
      of interest policy, please refer to www.asco.org/rwc or 
      ascopubs.org/op/authors/author-center. Open Payments is a public database 
      containing information reported by companies about payments made to US-licensed 
      physicians (Open Payments). NIQUELLE BROWN WADE: Employment: Cigna AJAY K. NOOKA: 
      Consulting or Advisory Role: Amgen, Janssen Oncology, Celgene, Spectrum 
      Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Takeda, Oncopeptides, 
      Karyopharm Therapeutics Research Funding: Amgen (Inst), Janssen Oncology (Inst), 
      Takeda (Inst) Travel, Accommodations, Expenses: GSK DANIEL STRAM: Employment: 
      Personalis (I) GRAHAM A. COLDITZ: Consulting or Advisory Role: Grail Patents, 
      Royalties, Other Intellectual Property: Royalties as author for UptoDate JAYESH 
      MEHTA: Honoraria: Celgene, Celgene (I), Takeda, Takeda (I), BMS, BMS (I), 
      Janssen, Janssen (I) Speakers' Bureau: Celgene, Celgene (I), Takeda, Takeda (I), 
      BMS, BMS (I), Janssen, Janssen (I) HOWARD TEREBELO: Consulting or Advisory Role: 
      Celgene Speakers' Bureau: Janssen Oncology SEEMA SINGHAL: Honoraria: Celgene, 
      Celgene (I), Takeda, Takeda (I), BMS, BMS (I), Janssen, Janssen (I) Honoraria: 
      Celgene, Celgene (I), Takeda, Takeda (I), BMS, BMS (I), Janssen, Janssen (I) RAVI 
      VIJ: Consulting or Advisory Role: Bristol-Myers Squibb, Celgene, Janssen, Sanofi, 
      Karyopharm Therapeutics, Jazz Pharmaceuticals, Amgen, Takeda, AbbVie Research 
      Funding: Amgen, Takeda, Celgene, Bristol-Myers Squibb Travel, Accommodations, 
      Expenses: Celgene, Bristol-Myers Squibb, Sanofi, Janssen, DAVAOncology, 
      Karyopharm Therapeutics, Amgen, Takeda, AbbVie LEON BERNAL-MIZRACHI: Employment: 
      Winship Cancer Institute, Kodikas Therapeutic Solutions, Takeda Science 
      Foundation Stock and Other Ownership Interests: Kodikas Therapeutic Solutions 
      Honoraria: Celgene Consulting or Advisory Role: Celgene Research Funding: Takeda 
      Patents, Royalties, Other Intellectual Property: We have discovered that 
      translocation of NFKB2 predicts response to proteasome inhibitors. Test has been 
      patented and licensed to Empire Genomics Travel, Accommodations, Expenses: 
      Celgene JEFFREY A. ZONDER: Consulting or Advisory Role: Celgene, Bristol-Myers 
      Squibb, Prothena, Janssen, Amgen, Takeda, Caelum, Intellia Therapeutics, Alnylam, 
      Oncotherapeutics Research Funding: Celgene (Inst), BMS (Inst) CAROL A. HUFF: 
      Consulting or Advisory Role: Karyopharm Therapeutics, Sanofi Genzyme, 
      GlaxoSmithKline, miDiagnostics, Janssen Research Funding: Ichnos (Inst) SAGAR 
      LONIAL: Consulting or Advisory Role: Celgene, Bristol-Myers Squibb, Janssen 
      Oncology, Novartis, GlaxoSmithKline, Amgen, AbbVie, Takeda, Merck, Juno 
      Therapeutics Research Funding: Celgene, Bristol-Myers Squibb, Takeda ROBERT Z. 
      ORLOWSKI: Consulting or Advisory Role: Amgen, Celgene, Ionis Pharmaceuticals, 
      Legend Biotech, Molecular Partners, Sanofi- Aventis, Servier, Takeda, Kite 
      Pharma, Juno Therapeutics, GSK Biologicals, FORMA Therapeutics, Bristol-Myers 
      Squibb, Janssen Biotech Research Funding: BioTheryX SIKANDER AILAWADHI: 
      Consulting or Advisory Role: Amgen, Takeda, Celgene, Janssen Biotech Research 
      Funding: Pharmacyclics (Inst), Janssen Biotech (Inst), Cellectar (Inst), 
      Phosplatin Therapeutics (Inst), Celgene (Inst) Travel, Accommodations, Expenses: 
      Amgen, Takeda, Novartis No other potential conflicts of interest were reported.
EDAT- 2020/05/30 06:00
MHDA- 2021/06/16 06:00
PMCR- 2021/10/01
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - 1900639 [pii]
AID - 10.1200/JOP.19.00639 [doi]
PST - ppublish
SO  - JCO Oncol Pract. 2020 Oct;16(10):e1169-e1180. doi: 10.1200/JOP.19.00639. Epub 
      2020 May 29.